S. Côté

发表

Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).

R. Momparler, S. Côté, L. Momparler, 2013, Leukemia research.

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells

Y. Idaghdour, R. Momparler, S. Côté, 2017, Front. Oncol..

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.

W. Miller, A. Bianchini, C. Nervi, 2002, Blood.

Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors.

W. Miller, A. Bianchini, C. Nervi, 2004, Blood.

Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.

W. Miller, A. Bianchini, C. Nervi, 2000, Blood.

Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia

S. Côté, N. Eliopoulos, R. Momparler, 1997, Leukemia.

Activation of the retinoic acid receptor β gene by 5-aza-2’-deoxycytidine in human DLD-1 colon carcinoma cells

R. Momparler, S. Côté, R. Momparler, 1997, Anti-cancer drugs.

Three new cases of terminal deletion of the long arm of chromosome 7 and literature review to correlate genotype and phenotype manifestations

R. Drouin, B. Maranda, M. Gadji, 2016, American journal of medical genetics. Part A.

DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine.

D. Sinnett, R. Momparler, S. Côté, 1999, Anti-cancer drugs.

EZH2 histone methyltransferase and induction of drug resistance to cytarabine in acute myeloid leukemia by 3-deazaneplanocin A

R. Momparler, S. Côté, L. Momparler, 2018 .

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.

S. Côté, N. Eliopoulos, R. Momparler, 1997, Leukemia.

Targeting of cancer stem cells by inhibitors of DNA and histone methylation

R. Momparler, S. Côté, 2015, Expert opinion on investigational drugs.

Identification and application of plasmatic microRNA expression quantitative trait loci (miR-QTL) at first trimester of pregnancy

P. Jacques, M. Hivert, L. Bouchard, 2021, medRxiv.

Demethylation by 5-aza-2´-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor ß gene in human colon carcinoma cells

D. Sinnett, R. Momparler, S. Côté, 1998, Anti-cancer drugs.

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation

Y. Idaghdour, R. Momparler, S. Côté, 2014, Clinical Epigenetics.

Evaluation of the antineoplastic activity of Adozelesin alone and in combination with 5‐aza‐2‐deoxycytidine and cytosine arabinoside on DLD‐1 human colon carcinoma cells

R. Momparler, S. Côté, 1993, Anti-cancer drugs.

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C

R. Momparler, S. Côté, L. Momparler, 2021, Epigenomes.

Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.

W. Miller, A. Bianchini, C. Nervi, 2000, Blood.

Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy

R. Momparler, S. Côté, L. Momparler, 2020, Epigenomes.

Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors.

W. Miller, A. Bianchini, C. Nervi, 2004, Blood.